Special Purpose Acquisition Company (SPAC) HORIZON SPACE ACQUISITION II Corp (NASDAQ: HSPT) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing the extension of its final business combination agreement deadline with SL Bio to April 18, 2026.

As part of the agreement, the company will pay a $50,000 extension fee. **Analysis of SPAC Merger Deadline Extension Mechanism** According to SEC filings, this extension is executed based on the terms of the original merger agreement signed by both parties. The SPAC structure typically sets a clear completion deadline; if the company fails to find a suitable merger target and complete the transaction within the specified timeframe, it faces the risk of liquidation. Horizon Space Acquisition II's exercise of the extension option demonstrates management's continued optimism about the SL Bio merger project. The $50,000 extension fee will be directly injected into the company's trust account to support the advancement of subsequent merger processes. **Challenges Facing the Space Industry M&A Environment** Currently, M&A activities in the space technology sector are undergoing a phase of adjustment. Elevated interest rates have increased financing costs for capital-intensive industries, while geopolitical factors have introduced uncertainties for cross-border technology integration. Meanwhile, several SPAC companies have entered liquidation procedures over the past year due to failure to complete mergers within the deadline, reflecting the market's cautious approach to early-stage space project valuations. Horizon Space Acquisition II's decision to extend the merger window demonstrates its confidence in SL Bio's technological assets and business model, as well as management's prudent attitude toward avoiding rushed transactions. **Market Impact Assessment of the Extension Decision** Following the announcement of the extension, market attention will shift to SL Bio's specific business progress. According to public information, SL Bio focuses on space applications research in the biopharmaceutical sector, and its technological roadmap aligns with recent innovation trends in drug development under microgravity conditions. Extending the merger timeline will provide both parties with more thorough technical due diligence and commercial negotiation space, but it also means investors must bear a longer capital lock-up period. Notably, the $50,000 extension fee is below the industry norm, which may suggest that negotiations between the parties have entered a relatively mature stage. **SPAC Market Evolution and Regulatory Dynamics** The US SEC has recently strengthened disclosure requirements for SPAC merger projects, emphasizing the need for more transparent presentation of financial forecasts and risk factors. This regulatory trend has generally extended the due diligence cycle in SPAC mergers. Horizon Space Acquisition II's decision to extend the timeline aligns with these market changes, providing a buffer to meet stricter compliance requirements. Industry data shows that since 2023, SPAC companies that have completed mergers have exhibited significant performance differentiation, with those possessing core technologies and clear profit paths being favored by the secondary market.